About: Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
Creator	Hage, Adam Rajsbaum, Ricardo Plante, Jessica Menachery, Vineet Popov, Vsevolod Kalveram, Birte Bente, Dennis Bradrick, Shelton Freiberg, Alexander Johnson, Bryan Rodriguez, Sergio Rossi, Shannan Ding, Zhixia Luo, Xuemei Mears, Megan Russell, William
Source	Medline; PMC
abstract	Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection. IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.
has issue date	2019-10-29(xsd:dateTime)
bibo:doi	10.1128/jvi.01282-19
bibo:pmid	31462558
has license	no-cc
sha1sum (hex)	f833af06053cca5a1e610c8d959c43c250afd801
schema:url	https://doi.org/10.1128/jvi.01282-19
resource representing a document's title	Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
has PubMed Central identifier	PMC6819921
has PubMed identifier	31462558
schema:publication	J Virol
resource representing a document's body	covid:f833af06053cca5a1e610c8d959c43c250afd801#body_text
is schema:about of	named entity 'integrity' named entity 'LPS' named entity 'activity' named entity 'lipopeptides' named entity 'cues' named entity 'severe acute respiratory syndrome coronavirus' named entity 'recapitulate' named entity 'vivo' named entity 'exploit' named entity 'microbial' named entity 'COMPONENTS' named entity 'VIRAL PATHOGENESIS' named entity 'USE' named entity 'EVALUATED' named entity 'INHIBITION' named entity 'FAILED' named entity 'ROLE' named entity 'FOUND' named entity 'PRODUCTS' named entity 'EXPLOIT' named entity 'SUGGEST' named entity 'viruses' named entity 'Bacillus' named entity 'wash' named entity 'virus' named entity 'Because' named entity 'infectivity' named entity 'infectivity' named entity 'commensal' named entity 'peptidoglycan' named entity 'bacterial' named entity 'antibiotic' named entity 'compound' named entity 'infection' named entity 'revealed' named entity 'bacterial' named entity 'Una' named entity 'influenza' named entity 'compound' named entity 'bacteria' named entity 'virion' named entity 'enveloped viruses' named entity 'surfactin' named entity 'LPS' named entity 'lipopeptides' named entity 'infectivity' named entity 'surfactin' named entity 'chikungunya' named entity 'SARS-CoV' named entity 'commensal' named entity 'microbial' named entity 'Zika' named entity 'MERS-CoV' named entity 'LPS' named entity 'infection' named entity 'Infectivity' named entity 'integrity' named entity 'implications' named entity 'molecule' named entity 'HCoV-229E' named entity 'HCoV-229E' named entity 'high levels' named entity 'intranasal' named entity 'infection' named entity 'virus' named entity 'lipid rafts'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software